PR- and ER-positive were more common in the HER2-zero and HER2-low groups, whereas the HER2-positive group had a larger tumor size, higher Ki-67 index, and a higher proportion of lymph node metastases and calcifications in the training and test cohorts. This evidence concerns the gene ERBB2 and neoplasm.